In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nuo Therapeutics, Inc.

http://www.nuot.com/

Latest From Nuo Therapeutics, Inc.

Start-Up Spotlight: Seqster Wants To Be The Mint.com Of Your Health-Care Data

San Diego, CA-based software-as-a-service company Seqster developed a technology that integrates data from electronic health records, genomics and wearables into one platform. Seqster's CEO Ardy Arianpour believes he has solved a major interoperability problem and hopes to attract providers, payers and pharma companies as clients.

Start-Up Spotlight StartUps and SMEs

Asia Deal Watch: Bharat Expands Its Vaccine Holdings By Buying GSK’s Chiron Behring

Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.

Commercial Deals

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

In Vitro Diagnostics Cancer

Market Intel: Artificial Intelligence Brings Wave Of Future Health Care Innovation – Embrace it or be Left Behind

Artificial intelligence and machine-learning will be the biggest disrupters in the health care industry, forcing a major shift in how companies innovate and operate, offering physicians unprecedented tools to diagnose and treat patients to improve outcomes and connecting patients like never before through consumer-driven devices. This feature takes a close look at how smaller companies and giants like Abbott, as well as national health care systems, are leveraging the power of AI to expedite innovation and product development in diabetes and other diseases. It highlights some of the latest studies that show how AI is being harnessed to improve imaging analytics, predict hard-to-find risk factors for heart disease and detect cancer, and discusses the critical role tech giants such as IBM, Google and Amazon continue to play in this space.

Artificial Intelligence Digital Health
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Other Names / Subsidiaries
    • Aldagen, Inc.
    • Cytomedix Inc.
UsernamePublicRestriction

Register